

## Appendix 1. Individual Patient Characteristics at Enrollment and Outcomes for Women Receiving Mifepristone 200 mg and Randomized to Progesterone or Placebo Treatment

Subject Number	Study group*	Age (years)	Gestational Age (days)	Race	Ethnicity	Education	Marital Status	Smoking	Alcohol	Marijuana Use	Drug Use	Total Pregnancies	Vaginal Delivery	Cesarean Delivery	Miscarriages	Abortions	Weight (kg)	BMI (kg/m <sup>2</sup> )
1	Progesterone	24.6	53	Asian	Not Hispanic	Some college	Never married	Never	Never	Never	Never	1	0	0	0	0	84.2	32.9
2	Progesterone	30.9	50	Black	Not Hispanic	Some college	Separated	Never	Current	Current	Never	8	3	0	0	4	68.9	23.8
3	Placebo	20.9	50	Asian	Not Hispanic	Some college	Never married	Never	Never	Never	Never	1	0	0	0	0	61.8	24.1
4	Placebo	22.6	48	White	Hispanic	Some college	Married	Current	Current	Current	Current	2	0	0	0	1	152.0	52.3
5	Progesterone	39.6	49	Black	Not Hispanic	Some college	Never married	Current	Never	Never	Never	5	2	0	0	2	51.8	19.0
6	Placebo	24.8	61	Asian	Not Hispanic	Some college	Never married	Never	Current	Current	Never	3	0	0	1	1	66.7	24.4
7	Placebo	23.5	48	White	Not Hispanic	High School graduate	Never married	Former	Never	Current	Never	7	0	1	0	5	71.8	22.7
8	Progesterone	27.7	56	Black	Not Hispanic	Some college	Never married	Never	Current	Never	Never	10	1	0	1	7	100.8	36.4
9	Progesterone	31.9	47	Asian	Not Hispanic	College graduate	Married	Never	Never	Never	Never	4	0	2	1	0	66.0	25.8
10	Placebo	27.0	60	Black	Not Hispanic	High School graduate	Never married	Never	Current	Current	Never	4	2	0	0	1	63.5	24.8
11	Placebo	33.8	60	White	Not Hispanic	Some college	Separated	Current	Former	Former	Former	12	6	0	0	5	105.5	34.3
12	Progesterone	28.6	48	Black	Hispanic	Some college	Divorced	Never	Current	Current	Never	3	1	0	0	1	53.8	19.7

Subject Number	hCG (mIU/mL)	Progesterone (ng/mL)	Exit Study Day <sup>†</sup>	FINAL OUTCOME	Hospital visit	Reason for Hospital visit
1	95,870	12.1	17	Continuing GCA at exit visit	No	N/A
2	57,681	11.5	16	Continuing GCA at exit visit	No	N/A
3	113,431	18.9	16	Continuing GCA at exit visit	No	N/A
4	25,450	13.7	4	No GCA at follow-up visit	No	N/A
5	107,780	24.1	16	Continuing GCA at exit visit	No	N/A
6	246,638	18.9	16	Continuing GCA at exit visit	No	N/A
7	73,018	11.2	4	D&C requested (bleeding, anxiety)	No	N/A
8	126,647	12.6	3	Expelled pregnancy, no D&C	Yes (ER), Day 3	Hemorrhage, hemoglobin 10.4 gm/dL
9	39,660	10.5	4	D&C requested (nausea, vomiting)	Yes (L&D), Day 3	Dehydration, nausea, vomiting
10	230,220	16.3	5	Expelled pregnancy, incomplete, emergent D&C	Yes (ER), Day 5	Hemorrhage, hemoglobin 9.6 gm/dL
11	194,384	16.7	6	Expelled pregnancy, incomplete, emergent D&C, transfusion	Yes (ER), Day 6	Hemorrhage, hemoglobin change 9.2 to 7.5 gm/dL
12	21,062	13.9	15	Continuing GCA at exit visit	No	N/A

BMI: body mass index; GCA: gestational cardiac activity; ER: emergency room; L&D: labor and delivery; N/A: not applicable

\* Initiated on study day 2 (24 hours after mifepristone ingestion)

† Day 1: day of mifepristone administration

Creinin MD, Hou MY, Dalton L, Steward R, Chen MJ. Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial. *Obstet Gynecol* 2020;135.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.